Marvelon 21

Nchi: Nyuzilandi

Lugha: Kiingereza

Chanzo: Medsafe (Medicines Safety Authority)

Viambatanisho vya kazi:

Desogestrel 0.15mg;  ; Ethinylestradiol 0.03mg;  

Inapatikana kutoka:

Merck Sharp & Dohme (New Zealand) Limited

INN (Jina la Kimataifa):

Desogestrel 0.15 mg

Dawa fomu:

Tablet

Tungo:

Active: Desogestrel 0.15mg   Ethinylestradiol 0.03mg   Excipient: Colloidal silicon dioxide DL-alpha Tocopheryl acetate Lactose monohydrate Magnesium stearate Potato starch Povidone Stearic acid

Vitengo katika mfuko:

Calendar pack, 3x21, 63 tablets

Darasa:

Prescription

Dawa ya aina:

Prescription

Viwandani na:

Aspen Oss B.V

Bidhaa muhtasari:

Package - Contents - Shelf Life: Calendar pack, 3x21 - 63 tablets - 36 months from date of manufacture stored at or below 25°C

Idhini ya tarehe:

1982-03-11

Tabia za bidhaa

Marvelon 21 A110120 Version 2.0 

Page 1 
RA 101 OS S7 (Ref 6.0) August 2008 

NEW ZEALAND DATA SHEET 
MARVELON
®
 21

Desogestrel plus ethinyloestradiol 

NAME OF MEDICINE 
Marvelon 21 
Tablets 
Desogestrel 0.15 mg; ethinyloestradiol 0.03 mg 

PRESENTATION 
Each pack of Marvelon 21 consists of: 21, white, round, (6 mm
diameter), biconvex tablets 
coded TR/5 on one side, and ORGANON and a star on the other side,
and containing 
desogestrel (a progestogen) 0.15 mg,
ethinyloestradiol (an oestrogen) 0.03 mg. 

USES 

ACTIONS 

ATC Classification G03A A09 

Marvelon 21 is a combined oral contraceptive (COC) preparation
containing as active 
substances the oestrogen, ethinyloestradiol, and the progestogen,
desogestrel.  Clinical 
studies have revealed that the oral contraceptive
preparations containing ethinyloestradiol 
and desogestrel lack undesirable metabolic effects.  These effects
are thought to result from 
the androgenic activity of some
progestogens in oral contraceptives.  Because of this, 
Marvelon 21 may have a favourable effect on androgen-related skin
disorders such as acne 
and hirsutism.  When taken according to the recommended dosage
scheme Marvelon 21 
suppresses the hypophyseal gonadal function and thereby ovulation. 
The contraceptive effect of COCs is based on the interaction of
various factors, the most 
important of which are seen as the inhibition of ovulation and the
changes in the cervical 
secretion.  Besides protection against pregnancy, COCs
have several positive properties 
which, next to the negative properties (see WARNINGS
AND PRECAUTIONS and ADVERSE 
EFFECTS), can be useful in deciding on the method of birth control.
 The cycle is more regular 
and the menstruation is often less painful and bleeding is lighter.
 The latter may result in a 
decrease in the occurrence of iron deficiency.  Apart from
this, there is evidence of a 
reduced risk